Budget impact of adding ivabradine to standard of care in patients with chronic systolic heart failure in the United States by Borer, Jeffrey S. et al.
 
 
 
 
 
Borer, J. S. et al. (2016) Budget impact of adding ivabradine to standard of 
care in patients with chronic systolic heart failure in the United States. 
Journal of Managed Care and Specialty Pharmacy, 22(9), pp. 1064-1071. 
(doi:10.18553/jmcp.2016.22.9.1064) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/128223/ 
     
 
 
 
 
 
 
Deposited on: 12 December 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Budget Impact of Ivabradine     1 
 
Budget Impact of Adding Corlanor® (Ivabradine) to Standard of Care in 
Patients with Chronic Systolic Heart Failure in the United States  
Jeffrey S. Borer,* Anuraag R. Kansal, PhD,† Emily D. Dorman, MPH, MBA,‡ Stanimira 
Krotneva, MSc, ‡ Ying Zheng, MHSA, MS,† Harshali K. Patel, MS, PhD, § Luigi Tavazzi,‖ 
Michel Komajda,¶ Ian Ford,# Michael Böhm,** Adrian Kielhorn§ 
 
*Division of Cardiovascular Medicine, The Howard Gilman Institute for Heart Valve Diseases 
and Ronald and Joan Schiavone Cardiovascular Translational Research Institute, State 
University of New York Downstate Medical Center, Brooklyn and New York, NY, USA; †Evidera, 
Bethesda, MD, USA; ‡Evidera, Montreal, QC H4T 1V6, Canada; §Amgen, Inc., Thousand 
Oaks, CA, USA; ‖ Maria Cecilia Hospital, GVM Care & Research, Ettore Sansavini Health 
Science Foundation, Cotignola, Italy; ¶Department of Cardiology, Pitié-Salpétrière Hospital, 
University Pierre et Marie Curie and IHU ICAN, Paris, France; #Robertson Centre for 
Biostatistics, University of Glasgow, Glasgow, Scotland; **Klinik für Innere Medizin III, 
Universitätsklinikum des Saarlandes, 66424 Homburg/Saar, Germany  
 
Address correspondence to: Jeffrey S. Borer, MD 
 SUNY Downstate Medical Center 
 47 East 88th Street  
 New York, NY 10128  
 Phone: 646-456-4454 
 email: jsborer1@gmail.com 
 
  
Budget Impact of Ivabradine     2 
 
Financial support and relationship with industry: JSB, MB, IF, and MK have received 
scientific support, consultative fees and/or speakers honoraria from Servier and Amgen; JSB 
also has received consultative fees from Celladon, Pfizer, ARMGO, Cardiorentis, Novartis, and 
Takeda USA; ARK, EDD, SK, and YZ are employees of Evidera; HP and AK are employees of, 
and stockholders in, Amgen; LT has received research grants and consultation fees from 
Servier. This study was funded by Amgen, Inc.  
 
  
Budget Impact of Ivabradine     3 
 
ABSTRACT 
Objectives: To estimate the budget impact of ivabradine from a US-commercial payer 
perspective. 
Background: Heart failure (HF) costs $21 billion annually in direct healthcare costs, 80% of 
which is directly attributable to hospitalizations. The SHIFT clinical study demonstrated that 
ivabradine plus standard-of-care (SoC) reduced HF-related and all-cause hospitalizations 
versus SoC alone.  
Methods: A budget impact model estimated the per-member-per month (PMPM) impact of 
introducing ivabradine to existing formularies by comparing a reference- (SoC) versus a new-
drug scenario (ivabradine+SoC) in hypothetical 1-million member commercial and Medicare 
Advantage plans. In both scenarios, US claims data were used for the reference cumulative 
annual rates of hospitalizations (HF, non-HF cardiovascular [CV], non-CV) and hospitalization 
rates were adjusted using SHIFT data. The model controlled for mortality risk using SHIFT and 
US life table data, and hospitalization costs were obtained from US claims data: HF-
related=$37,507; non-HF CV=$28,951; non-CV=$17,904. The annualized wholesale acquisition 
cost of ivabradine was $4,500, with baseline utilization for this new drug at 2%, increasing 
2%/year.  
Results: Based on the approved US indication, ~2000 commercially insured patients from a 1-
million member commercial plan were eligible to receive ivabradine. Ivabradine resulted in a 
PMPM cost savings of $0.01 and $0.04 in Years 1 and 3 of the Core Model, respectively. After 
including of acquisition price for ivabradine, the model showed decrease in total costs in the 
commercial ($991,256 and $474,499, respectively) and Medicare populations ($13,849,262 and 
$4,280,291, respectively) in Year 1; this was driven by ivabradine’s reduction in hospitalization 
rates. For the core model, the estimated pharmacy only PMPM in year 1 was $0.01 for the 
commercial population and $0.24 for Medicare Advantage plans. 
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Conclusions: Adding ivabradine to SoC led to lower average annual treatment costs. The 
negative PMPM budget impact indicates that ivabradine is an affordable option for US payers. 
What is already known about this subject: ivabradine reduces hospitalizations in patient with 
HF. Per US-FDA approval, ivabradine is indicated to reduce the risk of hospitalization for 
worsening heart failure in patients with stable, symptomatic chronic heart failure with left 
ventricular ejection fraction (LVEF) ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 
beats per minute and either are on maximally tolerated doses of beta-blockers or have a 
contraindication to beta-blocker use..  
 
What this study adds: Ivabradine has only recently (April 2015) been approved in the US, and 
the budget impact to commercial and Medicare plans in the US is yet unknown. This is the first 
study to assess the budget impact of introducing ivabradine into the US from a payer 
perspective. The clinical relevance of these results is that addition of ivabradine to treatment 
regimens in patients who meet FDA-approved indication for drug use can confidently expect to 
generate lower costs for their projected health benefits than if they did not use ivabradine. This 
may reduce costs to the individual patient and certainly will reduce costs to society as a whole.  
 
Key words: ivabradine, heart failure, heart rate, budget impact, economic modeling  
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INTRODUCTION 
Heart failure (HF) affects approximately 5.7 million Americans (1), and the risk for developing 
HF increases with age (2). Prognosis for patients with HF remains relatively poor, with the 5-
year survival rate estimated to be approximately 50% (3). In addition, HF is associated with a 
substantial economic burden, mainly because patients require frequent hospitalization, 
especially those with severe HF not controlled by standard medication (4). In 2010, direct 
medical costs associated with HF in the United States (US) were estimated to be approximately 
$21 billion, 80% of which was directly attributable to hospitalizations (1,5).  
Relatively high resting heart rate is an indication of inadequate HF control, and is an 
independent predictor of cardiovascular (CV)-related morbidity (hospitalizations) and mortality in 
patients with left ventricular systolic dysfunction and chronic symptomatic HF (6-10). In April, 
2015, the US Food and Drug Administration approved ivabradine to reduce the risk of 
hospitalization for worsening of HF in patients with stable, symptomatic, chronic HF with left 
ventricular ejection fraction (LVEF) ≤ 35%, who are in sinus rhythm with a resting heart rate ≥ 70 
beats per minute (bpm), and either are receiving maximally tolerated doses of or have a 
contraindication to beta-blockers. Because of the economic burden of HF, the objective of this 
study was to estimate the budget impact of introducing ivabradine into the formulary from a US 
payer perspective. 
METHODS 
Model Overview 
A Microsoft Excel-based budget impact model (Figure 1) was developed to compare a 
reference scenario, which included the current standard-of-care (SoC), with a new drug 
scenario in which ivabradine was added to current SoC. The analysis was based on a 
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hypothetical 1-million member US plan with a commercial (age 19 – 64 years) or Medicare 
Advantage (generally ≥ 65 years) population. Analytically, the model used the frequency and 
cost of hospitalizations of US patients with HF and applied an ivabradine-driven hospitalization 
reduction factor derived from the Systolic Heart Failure Treatment with the I(f)Inhibitor 
Ivabradine Trial (SHIFT)(8). The reduction in hospitalization costs and drug costs in the 
reference and new drug scenarios were then compared to assess the overall budget impact of 
ivabradine, expressed as incremental cost per member per month (PMPM). The model aimed to 
evaluate to what extent the cost of adding ivabradine to SoC was off-set by reductions in the 
cost of hospitalizations.  
Two versions of the model were developed: 1) a Core Model calculated the budget impact of 
adding ivabradine to SoC by considering only the effect of ivabradine on costs associated with 
hospitalization for worsening HF and the cost of ivabradine; and 2) an Expanded Model included 
all of the elements of the Core Model as well as the impact of ivabradine on all-cause 
hospitalization and the costs of treating adverse events (AE) related to ivabradine treatment. 
Both version of the model included the natural death rate of patients in this population based on 
the SHIFT SoC arm, supplemented with data from 2010 US life tables (11) and an analysis of 
mortality rates in patients with HF (12). The core and the expanded model were designed to 
estimate budget impact up to 5 years in future. For the purpose of simplicity and balance, the 
manuscript reports the results for year 1 and year 3.   
Model Inputs and Assumptions 
Ivabradine utilization expectation 
Based on projected drug utilization rates, the model used a utilization rate of 2% in Year 1 within 
the eligible patient population, with a 2% absolute increase for each subsequent year.  
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Epidemiology 
The model generated separate results for the commercial and Medicare Advantage populations. 
A retrospective database analysis was conducted using the OPTUM™ research database 
(Optum, Inc., Eden Prairie, MN) to estimate demographics, annual cumulative hospitalization 
rates, and hospitalization costs for the two populations. In the commercial population, the mean 
age was 63 years and 43% were female; in the Medicare Advantage population, the mean age 
was 77 years and 54% were female. 
The target eligible patient population for ivabradine was estimated from the literature and was 
defined as adults (≥ 18 years of age) with systolic chronic HF in New York Heart Association 
(NYHA) Class II, III, or IV, and normal sinus rhythm with a heart rate of ≥ 70 bpm. The target 
population sizes were calculated as the sum of prevalent and incident cases in the US 
commercial and Medicare populations estimated using multiple inputs (5,13-15), such as NYHA 
Class and heart rate (Table 1). The epidemiological makeup of the target population was 
assumed to remain constant across the model time horizon, consistent with American Heart 
Association methodology (5).  
Clinical Inputs 
Ivabradine efficacy was derived using data from SHIFT, in which 6,505 patients with moderate-
to-severe (NYHA Class II, III, or IV) HF in normal sinus rhythm, with LVEF ≤ 35% and heart rate 
≥ 70 bpm, and with a HF-related hospitalization within the past year, were randomized to 
ivabradine or placebo in addition to maximally tolerated beta-blockers and other guideline-
suggested drug therapies (8). The model had ability to utilized annualized hospitalization rates 
either from clinical trial data (SHIFT) or real world US claims (OPTUM claims). The results 
obtained using real world US hospitalization rates are reported in this manuscript.  The mortality 
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inputs used in this model reflect natural death rates(Table 2).  To align with ivabradine’s US 
label, mortality benefit due to use of Ivabradine was not considered in this model.  
To derive clinical inputs for patients treated with ivabradine in the new drug scenario, 
hospitalization rates from the reference case were adjusted based on treatment effect data 
derived from a post hoc analysis of the SHIFT trial population (incident rate  ratio [IRR]= 0.75 
over the duration of the entire trial [median = 22.9 months]) (10). For the Expanded Model which 
included all-cause hospitalization, annualized incidence rates for each type of hospitalization 
were calculated using the intent-to-treat set as the total number of events divided by the total 
number of patient-years at risk (from randomization until death or the end of study, whichever 
came first). The model calculated mutually exclusive hospitalization rates and costs for HF-
related, non-HF CV related, and non-CV related hospitalizations to avoid double-counting of 
events that could occur if the overlapping categories of “all-cause” and “CV-related” were used. 
Mortality benefit due to adding ivabradine to SoC was not included in either model.   
Cost Inputs 
Because ivabradine is intended to be used as an add-on therapy and not expected to impact 
use of SoC, the costs of SoC drugs were excluded from the model. Hospitalization cost inputs 
were calculated from OPTUM research database for both populations. InGauge data that 
included commercial fee ranges and geographic adjustment factors were used for adverse 
event-related costs (16) (Table 3). The hospitalization costs were estimated separately for the 
commercial and Medicare Advantage populations. All hospitalization cost inputs were based on 
insurer-paid claims (13,17) and did not include patient out-of-pocket costs or adjustment for 
coordination of benefits among more than one insurer. Therefore, the cost of hospitalization 
used in this model may not reflect the total cost. The cost for ivabradine was $4,500 per year for 
every patient included in the model, the wholesale acquisition cost as of April 15, 2015.  
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The Expanded Model included a wider scope of the additional inputs related to the cost of all-
cause hospitalization and AEs. Costs associated with non-HF CV- and non-CV-related 
hospitalizations were estimated from the OPTUM research database. Using the SHIFT safety 
dataset, rates of AEs for both the reference and new drug scenarios were calculated as the total 
number of AEs divided by the number of patient-years at risk. AEs included in the model were 
asymptomatic bradycardia, symptomatic bradycardia, atrial fibrillation, phosphenes, and blurred 
vision. These AEs were selected because in SHIFT, they were among the most-frequent AEs 
overall and the incidence differed between the ivabradine and placebo arms; in addition, they 
are potentially related to ivabradine’s mechanism of action (8). Costs of AE management 
included cost of outpatient physician visits or emergency department visits for cardiac events of 
moderate or high severity and cost of comprehensive ophthalmological services for ophthalmic 
events (17).  
Sensitivity Analyses 
Multiple one-way sensitivity analyses were conducted to understand the impact of varying core 
model inputs and assumptions on the results (Table 5). In accordance with the International 
Society for Pharmacoeconomics and Outcomes Research guidance on budget impact analyses 
(18), alternative scenarios of potential interest to payers were tested using the Expanded Model, 
which considered the budget impact of all-cause hospitalizations and AEs in addition to HF-
related hospitalizations.  
RESULTS 
Core Model Results 
In a hypothetical 1 million member plan, 1,913 commercially insured prevalent patients and 191 
incident patients (total n= 2104)were eligible to receive ivabradine. Based on 2% utilization for 
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year 1, a total of 38 patients will utilize Ivabradine and this will increase to 115 patients in year 3. 
In the US commercial plan population, ivabradine costs at Year 3 were estimated to be 
$516,757. Eligible patients treated with SoC would incur an estimated total cost of 
$66,616,644due to HF-related hospitalizations. Patients treated with ivabradine plus SoC would 
incur an estimated total cost of $65,625,389due to fewer HF-related hospitalizations – a cost 
savings of $991,256. After accounting for the cost of providing ivabradine ($516,757), the net 
result was a saving of $474,499, resulting in an incremental cost savings of $0.04 PMPM 
compared with the SoC scenario (Table 4). 
In the Medicare Advantage population, the introduction of ivabradine resulted in an incremental 
cost savings of $0.36 PMPM compared with the SoC scenario at Year 3. The larger favorable 
budget impact in the Medicare Advantage plan compared with the commercial plan was driven 
by a combination of higher prevalence and incidence of HF and the higher rates of HF-related 
hospitalization, which would be expected in this older population (Table4).  
Expanded Model Results 
Including the costs of AE management and all-cause hospitalization in the Expanded Model still 
resulted in PMPM cost savings of $0.05 in the commercial and $0.52 in the Medicare 
Advantage populations (Table 4). 
Sensitivity Analyses 
Results from one-way sensitivity analyses performed on the Core Model with commercial and 
Medicare Advantage populations are summarized in Table 5. The use of alternative 
hospitalization rates from the SHIFT study resulted in an incremental cost increase of $0.02 
PMPM and $0.59 PMPM for the commercial and Medicare Advantage populations, respectively. 
These changes were driven by lower overall rates of hospitalization in the SHIFT study relative 
to US claims data, resulting in smaller cost offsets from prevented hospitalizations (Table 5). 
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Using US claims data, longer model timeframes were associated with increasingly favorable 
budget impacts: extending the time horizon from 3 to 5 years increased incremental cost 
savings to $0.07 PMPM and $0. 627 PMPM for the commercial and Medicare Advantage 
populations, respectively. Decreasing the time horizon to 1 year reduced cost savings to $0.01 
PMPM for the commercial and $0.11 PMPM for the Medicare Advantage populations. Similarly, 
greater market penetration was associated with increasingly favorable cost savings: a low 
uptake scenario of 1% per year resulted in incremental cost savings of $0.02 PMPM for the 
commercial and $0. 180 PMPM for Medicare Advantage populations, whereas a high 
utilizationscenario of 5% per year resulted in incremental cost savings of $0.10 PMPM and 
$0.89 PMPM at Year 3 for commercial and Medicare Advantage populations, respectively. 
Decreasing the ivabradine acquisition cost by 20% increased cost savings to $0.05 PMPM and 
$0.52 PMPM, while an increase of 20% reduced cost savings to $0.03 PMPM and $0.22 
PMPM, respectively (Table 5).  
DISCUSSION 
The results of this budget impact analysis indicate that the reduced hospitalizations associated 
with adding ivabradine treatment to SoC in a  the eligible patient population (8) would result in 
overall cost savings for US commercial and Medicare Advantage plan formularies. Cost savings 
were primarily driven by reductions in HF-related hospitalizations, which offsets the costs of 
ivabradine. Cost offsets were greater in the Medicare Advantage population than in the 
commercial plan population, and this was because of the much greater prevalence of HF and 
higher rates of HF-hospitalization in the older population represented in the Medicare 
Advantage database. Together, these findings demonstrate a consistently favorable budget 
impact in both populations. These data are useful because chronic HF is associated with a 
relatively high economic burden, and SHIFT demonstrated that for patients with chronic HF with 
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moderate-to-severe systolic dysfunction, targeted reduction in heart rate with ivabradine 
treatment in combination with SoC resulted in significant reductions in hospitalization rates (8). 
The patient populations targeted in these models were as close as possible to those covered by 
the approved US indication for ivabradine, including patients both with and without a previous 
HF-related hospital admission. This is in contrast to the SHIFT study population, which included 
admission within the year prior to study enrollment and LVEF ≤ 35% as inclusion criteria (8). 
While the model assumes similar benefits of adding ivabradine treatment in the broader 
population, a clear benefit of ivabradine in reducing the risk of HF-related hospitalization in 
patients without a previous admission has not been rigorously established in clinical trials.  
Sensitivity analyses showed that for the commercially-insured population, the biggest drivers of 
budget impact were hospitalization rates and ivabradine utilization. Together, these results 
suggest that the economic benefit of adding ivabradine to SoC will be substantially influenced 
by access to treatment, particularly in patient populations at progressively higher risk for HF-
related admissions.  
This is the first study to assess the budget impact of introducing ivabradine into the US. A 
separate budget impact analysis by the National Institute for Health and Care Excellence (NICE) 
in the United Kingdom estimated the total budget impact as approximately £4,400 per 100,000 
individuals (19). This moderate budget impact together with a favorable assessment of the 
clinical efficacy resulted in a positive recommendation for ivabradine by NICE in the UK.  
The strength of the current analysis is that it used data from real-world US medical commercial 
claims to derive hospitalization rates and costs in both the commercial and Medicare Advantage 
populations, thus making the results highly relevant to the target US populations. Similarly, the 
natural death rates of non-CV mortality were adjusted using data from US life tables to ensure 
that mortality rates were as relevant to the target population as possible.  
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It is important to note that the cost of SoC was not included in the model, resulting in 
underestimation of total treatment costs. However, because ivabradine is intended to be used in 
addition to SoC, exclusion of these costs does not affect incremental budget impact. Due to 
data limitations, costs of AE management in the Expanded Model considered only those costs 
associated with outpatient and emergency room visits, and did not include costs of AE 
associated tests, procedures, or medications; this may have led to an underestimate of the total 
costs associated with AE management. In addition, although the analysis suggested that 
incremental budget impact was relatively insensitive to AE cost, some costs related to AE 
management may be associated with inpatient visits (e.g., for symptomatic atrial fibrillation). 
Although these costs would be captured as a component of all-cause hospitalization, they would 
not be specifically attributed to AE management. 
In conclusion, inclusion of ivabradine in the formularies of US commercial and Medicare 
Advantage plans in the US is estimated to result in a reduction of HF-related hospitalizations 
that offset the cost of providing ivabradine to patients. From a US payer perspective, the 
favorable budget impacts associated with ivabradine treatment indicate that ivabradine will be 
an affordable treatment option in both populations.  
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FIGURE LEGENDS 
Figure 1. An overview of the budget impact model for ivabradine in patients in the United States 
with heart failure in a commercial or Medicare Advantage plans 
PMPM, per patient per month 
Figure 2. Patients with heart failure in the United States who are eligible for ivabradine 
* OPTUM research analysis 
† STAMINA registry (data on file) 
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Table 1. Epidemiology Parameters for a 1-million Member Hypothetical Health Care Plan 
  Commercial Population Medicare Advantage Population 
Model Population Parameter Frequency, % Patients, N Frequency, % Patients, N 
Hypothetical Plan Membership 
 
1,000,000 
 
1,000,000 
Prevalence of chronic heart failure 1.0%* 10,000 16.0%† 160,000 
Chronic HF patients with systolic chronic HF 52.9%‡ 5,290 52.9%‡ 84,640 
With normal sinus rhythm 66.8%§ 3,534 66.8%§ 56,540 
With normal sinus rhythm and NYHA Class II to IV 88.3%§ 3,120 88.3%§ 49,924 
With normal sinus rhythm and NYHA Class II to IV 
with heart rate of >70 bpm 61.3%‖ 1,913 61.3%‖ 30,604 
Incidence of chronic heart failure 0.1% 1,000 3.1% 31,000 
Chronic HF patients with systolic chronic HF 52.9%‡ 529 52.9%‡ 16,399 
With normal sinus rhythm 66.8%§ 353 66.8%§ 10,955 
With normal sinus rhythm and NYHA Class II to IV 88.3%§ 312 88.3%§ 9,673 
With normal sinus rhythm and NYHA Class II to IV 
with heart rate of >70 bpm 61.3%‖ 191 61.3%‖ 5,929 
Total patients eligible for treatment (prevalent + incident populations)   2,104   36,533 
bpm = beats per minute; HF = heart failure; NYHA = New York Heart Association 
*(12); †(13); ‡(14); §(15); ‖STAMINA registry 
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Table 2. Hospitalization, Mortality, and AE Rates for Patients with Chronic Systolic HF by Data Source. 
 
 US Claims Data SHIFT Trial Data* 
Parameter Commercial† Medicare 
Advantage† 
Placebo + 
SoC 
Placebo + 
Ivabradine 
Incident Rate Ratios  
(95% Confidence 
Interval)~ 
Hospitalizations       
HF-related (base case) 0.928 1.144 0.204 0.151^ 0.75 (0.65-0.87) 
Non-HF CV-related (sensitivity 
analysis) 
0.070 0.093 0.179 0.169^ 0.95 (0.84-1.07) 
Non CV-related (sensitivity 
analysis) 
0.524 0.645 0.142 0.126^ 0.88 (0.75-1.04) 
Mortality      
HF-related -- -- 0.026 0.019^ 0.74 (0.58 – 0.94) 
Non-HF CV-related -- -- 0.057 0.056^ 0.98 (0.84 – 1.14)  
AEs (alternative scenario 
analyses) 
     
Asymptomatic bradycardia -- -- 0.8% 3.6%  
Symptomatic bradycardia -- -- 0.6% 2.9%  
Atrial fibrillation -- -- 4.6% 5.8%  
Phosphenes -- -- 0.1% 0.4%  
Blurred vision -- -- 0.3% 1.8%  
 
CV = cardiovascular; HF = heart failure; SoC = standard of care 
*(8); †OPTUM research data analysis; ~Incident rate ratios represent Placebo + Ivabradine vs. Placebo +SoC; ^ivabradine rates are 
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presented for exemplary purposes but are not used as inputs in the model 
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Table 3. Cost Inputs in US Dollars 
Cost Input Commercial Population Medicare Advantage Population 
Ivabradine acquisition, cost per year $4,500  $4,500  
Hospitalization, cost per event 
  
HF-related (Core Model) $37,507  $22,956 
Non-HF CV-related (expanded model) 
$28,951  $18,127 
All-cause (Expanded Model) $17,904  $11,489 
AE, cost per event (alternative scenario)† 
  
Asymptomatic bradycardia $142§  $73‖  
Symptomatic bradycardia $686¶  $367#  
Atrial fibrillation $686¶ $367# 
Blurred vision $187**  $126†† 
Phosphenes $187** $126†† 
AE = adverse event; CV = cardiovascular; HF = heart failure 
 
† Includes cost of a physician visit for management of CV-related event of moderate or high severity, ED visit for a CV-related event 
of high severity, and comprehensive ophthalmological services for an ophthalmic event 
§ Physicians' Fee and Coding Guide, CPT code 99213 (InGauge Healthcare Solutions, 2014) 
¶ Sum of Physicians' Fee and Coding Guide, CPT code 99213 ($142) and Physicians' Fee and Coding Guide, CPT code 99284 
($544) (InGauge Healthcare Solutions, 2014) 
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# Sum of CMS. Physician Fee Schedule Look-Up Tool. National Payment Amount by CPT Code. CPT code 99213 ($73) CY 2014 
and CMS. Hospital Outpatient PPS File. CPT code 99284 (294) CY July 2014 
** Physicians' Fee and Coding Guide, CPT code 92014 ($187) (InGauge Healthcare Solutions, 2014) 
†† CMS. Physician Fee Schedule Look-Up Tool. National Payment Amount by CPT Code. CPT code 92014 (126) CY 2014 
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Table 4. Cost Projections at Year 3 After Hospitalization for the Hypothetical One-million Member Insurance Plans in US Dollars*  
 
 
 
  Commercial†  Medicare Advantage† 
 Costs 
Reference 
Scenario§ 
New Drug 
Scenario¶  
Incremental 
Difference 
Reference 
Scenario§  New Drug Scenario¶  
Incremental 
Difference 
Core Model 
      
Drug acquisition $0.00 $516,757 $516,757 $0.00 $9,568,971 $9,586,971 
HF-related 
hospitalization  
$66,616,644 $65,625,389 ($991,256) $930,729,958 $916,880,696 ($13,849,262) 
Total costs $66,616,644 $66,142,146 ($474,499) $930,729,958 $926,449,667 ($4,280,291) 
Cost PMPM $5.55 $5.51 ($0.04) $77.56 $77.20 ($0.36) 
Expanded Model (Core Model + All-cause hospitalization and effect 
of AEs) 
   
Drug 
acquisition 
$0.00 $516,757 $516,757 $0.00 $9,568,971 $9,568,971 
HF-related 
hospitalization  
$66,616,644 $65,625,389 ($991,256) $930,729,958 $916,880,696 ($13,849,262) 
CV-related 
hospitalization 
$70,495,325 $69,491,735 ($1,003,590) $990,476,165 $976,436,910 ($14,039,255) 
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All-cause 
hospitalization 
$88,451,086 $87,320,369 ($1,130,717) $1,253,105,598 $1,237,206,927 ($15,898,671) 
AEs $71,756 $75,380 $3,264 $713,815 $750,446 $36,631 
Total costs $88,522,842 $87,912,506 ($610,336) $1,253,819,413 $1,247,526,344 ($6,293,069) 
Cost PMPM $7.38 $7.33 ($0.05) $104.48 $103.96 ($0.52) 
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* No discount rate was applied 
† Values in parentheses represents cost savings to the health plan 
§ SoC 
¶ Ivabradine + SoC 
 
AE = adverse event; HF = heart failure; CV=cardiovascular; PMPM = per member per month; SoC = standard of care 
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Table 5. One-way Sensitivity Analysis 
 Parameter Core model Value SA Value Commercial 
Incremental Cost 
(PMPM)* 
Medicare Advantage 
Incremental Cost 
(PMPM)* 
Data source for hospitalization rates 
US-claims; 
commercial 
perspective 
SHIFT trial; 
commercial 
perspective 
$0.02 $0.59 
Time horizon 3 years 5 years ($0.07) ($0.62) 
  1 year ($0.01) ($0.11) 
Ivabradine utilization 
2% in Year 1 
2% increase each 
year 
1% in Year 1 
1% increase each 
year 
($0.02) ($0.18) 
  
5% in Year 1 
5% increase each 
year 
($0.10) ($0.89) 
Ivabradine acquisition cost $4,500 
$3,600  
(20% decrease) 
($0.05) ($0.52) 
  
$5,400  
(20% increase) 
($0.03) ($0.20) 
Hospitalization events HF-related CV-related ($0.04) ($0.37) 
  All-cause ($0.05) ($0.53) 
CV, cardiovascular; HF = heart failure; PMPM = per member per month; SA = sensitivity analysis; SHIFT = Systolic Heart Failure 
Treatment with the I(f) Inhibitor Ivabradine Trial 
* Values in parentheses represent cost savings to the health plan  
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Figure 1 
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Figure 2 
 
 
 
 
 
 
